6 citations
,
November 2015 in “JAMA” Oral contraceptives help mild hirsutism, while flutamide and spironolactone help severe cases.
5 citations
,
January 1991 in “Drugs of The Future” December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
10 citations
,
September 2015 in “Gynecological Endocrinology” Both treatments reduced excessive hair growth in PCOS, but there was no difference in weight, hair score, hormone levels, or insulin resistance.
January 2002 in “Medisch-Farmaceutische Mededelingen” Finasteride is not effective for older women with hair loss.
32 citations
,
July 2001 in “Endocrine Practice” Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.
April 2020 in “Journal of the Endocrine Society” An ovarian tumor caused a woman's male-like symptoms, which improved after surgery.
1 citations
,
May 2022 in “Revista Contemporânea” Combining two treatments for hair loss works better than using just one.
The document concludes that antiandrogenic drugs like cyproterone acetate and spironolactone are effective but not permanent treatments for skin-related androgenization in women.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
January 2002 in “HAL (Le Centre pour la Communication Scientifique Directe)” The enzyme system in hair follicles is similar to the liver's and is inhibited by certain substances.
May 2022 in “Reactions Weekly” November 2025 in “Food Science & Nutrition” Apigenin may effectively promote hair growth for androgenetic alopecia when applied topically.
October 2025 in “Minerva Obstetrics and Gynecology” Choosing the right estroprogestin is crucial for effectively managing PCOS symptoms.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
4 citations
,
April 2016 in “Journal of Dermatology Research and Therapy” Anti-androgens are safe and effective for treating moderate to severe adult female acne.
2 citations
,
January 2025 in “JAAD Case Reports” Topical metformin may improve hair regrowth in CCCA when added to standard treatments.
December 2013 in “Open Access Macedonian Journal of Medical Sciences” A woman's excessive hair growth and high testosterone were caused by a rare ovarian tumor, which was successfully treated with surgery.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
1 citations
,
December 2025 in “Baylor University Medical Center Proceedings” Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.
April 2023 in “Research Square (Research Square)” A young woman had a rare, aggressive ovarian tumor that was hard to diagnose and treat, leading to disease progression despite treatment.
January 2014 in “Jaypee Brothers Medical Publishers (P) Ltd. eBooks” Bimatoprost may help with hair loss.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
2 citations
,
January 2021 in “PLANT ARCHIVES” Andrographolide-loaded topical nanocarriers are a safe and effective treatment for psoriasis.
May 2022 in “The Journal of Clinical Pharmacology” Metformin reduces certain hormone levels in men with early-onset hair loss.
4 citations
,
May 2022 in “Genes & Diseases”
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
4 citations
,
August 2024 in “PLoS ONE” Both injectable contraceptives lower testosterone and SHBG levels, with NET-EN having a greater effect than DMPA-IM.